Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $19.8750.

JSPR has been the subject of several research reports. Rodman & Renshaw began coverage on Jasper Therapeutics in a report on Tuesday, January 13th. They set a “buy” rating and a $17.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of Montreal Can grew its position in Jasper Therapeutics by 120.4% during the second quarter. Bank of Montreal Can now owns 158,133 shares of the company’s stock worth $878,000 after buying an additional 86,393 shares in the last quarter. Simplify Asset Management Inc. bought a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at $1,450,000. Marex Group plc bought a new stake in shares of Jasper Therapeutics during the 2nd quarter valued at $74,000. Kingdon Capital Management L.L.C. grew its holdings in shares of Jasper Therapeutics by 93.5% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock worth $3,153,000 after purchasing an additional 640,138 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of Jasper Therapeutics in the third quarter worth $96,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $1.38 on Thursday. The stock has a market cap of $38.61 million, a PE ratio of -0.23 and a beta of 3.08. The firm has a 50-day moving average of $1.69 and a 200-day moving average of $2.21. Jasper Therapeutics has a 52-week low of $1.33 and a 52-week high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.12). As a group, analysts predict that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.